Fill-Finish Services CROs

Leading CDMO providing custom development and manufacturing for the pharmaceutical and biotech industries. Lonza specializes in biologics, cell and gene therapy, and small molecule manufacturing.

Global leader in drug delivery technologies and development solutions. Catalent provides formulation, development, and manufacturing services for pharmaceuticals, biologics, and consumer health products.

Leading CDMO providing pharmaceutical manufacturing services including development, scale-up, and commercial production of oral solids, sterile products, and complex formulations.

CDMO division of Eurofins providing process development, analytical development, and GMP manufacturing for biopharmaceutical products including monoclonal antibodies and recombinant proteins.

UK-based CDMO specialising in inhaled drug product development including dry powder inhalers, metered dose inhalers, and nasal spray formulations.

CDMO headquartered in Northern Ireland providing GMP API synthesis, drug product development, clinical trial supply manufacturing, and biomarker services across North America and Europe.

Global CDMO offering end-to-end pharmaceutical development and manufacturing including API synthesis, oral solid dose, sterile fill-finish, and antibody-drug conjugate manufacturing.

Specialist CDMO for cell and gene therapy products offering GMP clinical and commercial manufacturing and development solutions for ATMPs from German, US, and Japanese facilities.

Independent pharmaceutical development services company in Basel providing drug formulation development, analytical development, and stability testing for injectable and biopharmaceutical products.

Labcorp's contract development and manufacturing arm providing formulation development, analytical services, stability testing, and clinical trial manufacturing for small molecules and biologics.

Major global CDMO providing end-to-end pharmaceutical development and manufacturing services including drug substance, drug product, and commercial manufacturing under the Thermo Fisher Scientific umbrella.

CDMO providing custom API development and manufacturing, solid dose and sterile formulation, analytical testing, and clinical and commercial supply from multiple US facilities.

CDMO offering integrated drug discovery, development, and manufacturing services including API production, drug product manufacturing, and analytical services from facilities in the US, Europe, and India.

Indian biopharmaceutical company providing biosimilar development, contract manufacturing, and clinical research services with GMP manufacturing facilities for biologics and biosimilars.

US biologics CDMO providing cell line development, process development, cGMP manufacturing, and analytical services for monoclonal antibodies, recombinant proteins, and gene therapy products.

Specialized CDMO focused exclusively on sustained-release long-acting injectable formulation development, aseptic fill-finish, and lyophilization.

Contract research and manufacturing organization offering drug discovery, API synthesis, analytical development, and formulation services to global pharma and biotech.

Gene therapy-focused CDMO providing viral vector manufacturing for adeno-associated virus (AAV) gene therapies, acquired by Catalent to expand biologics capabilities.

Global biologics CDMO providing end-to-end solutions for biologics drug development and manufacturing including monoclonal antibodies, bispecific antibodies, ADCs, and cell and gene therapies.

WuXi AppTec's pharmaceutical development and manufacturing arm providing API process development, formulation development, analytical services, and GMP manufacturing from China and US facilities.

South Korean biosimilar developer and CDMO providing biologics development, manufacturing, and analytical services with a portfolio of approved biosimilar products across global markets.

South Korean biopharmaceutical company providing biosimilar development and cGMP biologics manufacturing with one of the largest mammalian cell culture facilities in the world.

CMIC Group's contract manufacturing arm providing GMP drug product manufacturing, formulation development, and packaging services from Japanese facilities.

WuXi AppTec's cell and gene therapy division providing GMP viral vector manufacturing, cell therapy manufacturing, and plasmid DNA production from US and China facilities.

Biologics CDMO providing GMP manufacturing of viral vaccines, recombinant proteins, and gene therapy vectors from BSL-2/3 facilities, with particular expertise in infectious disease and oncology.

Top-tier biologics CDMO offering cell culture, microbial fermentation, and cell and gene therapy manufacturing across US sites supporting 128+ regulatory approvals.

Belgian CDMO providing integrated drug substance and drug product development from early-phase API synthesis through formulation, analytical development, and GMP manufacturing.

Swiss CDMO providing integrated drug substance and drug product development services including API synthesis, process development, and highly potent compound manufacturing.

European CDMO with 13 production sites across seven countries providing oral solid dose, softgel, and sterile manufacturing for pharma and biotech clients.

Indiana-based aseptic fill-finish CDMO specialising in small-batch sterile injectable manufacturing for cell therapies, gene therapies, and biologics.

US-German CDMO specialising in viral vector and oncolytic virus manufacturing for gene therapy and immuno-oncology clinical programmes.

San Diego-based CDMO providing small and large molecule API manufacturing, oligonucleotide synthesis, and ADC conjugation services from pre-clinical through commercial scale.

US CDMO providing drug substance manufacturing, fill-finish, and device assembly services for biologics, vaccines, and cell/gene therapy products.

European CDMO network with 11 GMP facilities providing integrated API, drug product, and packaging services from pre-clinical through commercial scale including peptides, lipids, and injectables.

German CDMO specialising in sterile liquid fill-finish, lyophilisation, and oral solid dosage manufacturing for clinical and commercial supply.

Greek CDMO specialising in long-acting injectable (LAI) and controlled-release oral solid dosage development and manufacturing for complex generics and NCEs.

French CDMO specialising in topical, semi-solid, and liquid pharmaceutical manufacturing for clinical trial supply and commercial production.

Hungarian pharmaceutical company's CDMO division offering API synthesis, steroids manufacturing, and hormone product development from GMP-certified facilities.

Tokyo-based CRO and CDMO providing contract manufacturing of injectable formulations, lyophilized products, and sterile fills for Japanese and international pharmaceutical clients.

Munich-headquartered European CDMO providing development and manufacturing of solid oral dosage forms, capsules, and effervescent tablets with 12 GMP manufacturing sites across Europe.

Uppsala-based Swedish CDMO providing pharmaceutical development, manufacturing, and sterile fill-finish services with expertise in complex injectables and lyophilized products.

Swiss CDMO providing API synthesis, lipid nanoparticle manufacturing, and peptide production, known for large-scale mRNA lipid supply and complex pharmaceutical intermediates.

Korean CDMO providing development and GMP manufacturing of solid oral dosage forms, injectables, and biosimilars, with FDA and EMA-inspected facilities serving global markets.

Global CDMO with 30+ years delivering development and manufacturing for biologics, cell therapies, viral vectors, and mRNA across US, European, and Asian facilities.

Cell and gene therapy CDMO with purpose-built cGMP facilities in Edinburgh and Hopkinton, Massachusetts, supporting clinical and commercial advanced therapy programs.

Global CDMO with integrated small molecule, biologics, and gene therapy manufacturing including proprietary viral vector platforms across the US, Europe, and Asia.

Gene therapy and viral vector CDMO in Columbus, Ohio, with 20+ years of leadership and 500+ GMP drug substance batches produced for rare and ultra-rare disease programs.

Australian CDMO providing API manufacturing, sterile fill-finish, and pharmaceutical development services from TGA-licensed and FDA-registered facilities in Melbourne.

US-based biomanufacturing CDMO founded in 2020 delivering end-to-end development and manufacturing for biologics, mRNA, and cell and gene therapy across a domestic facility network.

Leading CDMO providing end-to-end biopharmaceutical manufacturing services including cell line development, process development, and commercial manufacturing at massive scale.